- Home
- NOM vs INTS Comparison
NOM vs INTS Comparison
Compare NOM & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOM
- INTS
- Stock Information
- Founded
- NOM 1993
- INTS 2012
- Country
- NOM United States
- INTS United States
- Employees
- NOM N/A
- INTS N/A
- Industry
- NOM Investment Managers
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- NOM Finance
- INTS Health Care
- Exchange
- NOM Nasdaq
- INTS Nasdaq
- Market Cap
- NOM N/A
- INTS 30.8M
- IPO Year
- NOM N/A
- INTS 2023
- Fundamental
- Price
- NOM $10.35
- INTS $1.89
- Analyst Decision
- NOM
- INTS Strong Buy
- Analyst Count
- NOM 0
- INTS 3
- Target Price
- NOM N/A
- INTS $8.50
- AVG Volume (30 Days)
- NOM 6.9K
- INTS 36.8K
- Earning Date
- NOM 01-01-0001
- INTS 05-08-2025
- Dividend Yield
- NOM 3.39%
- INTS N/A
- EPS Growth
- NOM N/A
- INTS N/A
- EPS
- NOM N/A
- INTS N/A
- Revenue
- NOM N/A
- INTS N/A
- Revenue This Year
- NOM N/A
- INTS N/A
- Revenue Next Year
- NOM N/A
- INTS N/A
- P/E Ratio
- NOM N/A
- INTS N/A
- Revenue Growth
- NOM N/A
- INTS N/A
- 52 Week Low
- NOM $8.52
- INTS $1.50
- 52 Week High
- NOM $10.48
- INTS $5.28
- Technical
- Relative Strength Index (RSI)
- NOM 38.67
- INTS 40.78
- Support Level
- NOM $10.26
- INTS $1.81
- Resistance Level
- NOM $10.52
- INTS $2.07
- Average True Range (ATR)
- NOM 0.09
- INTS 0.19
- MACD
- NOM 0.03
- INTS -0.01
- Stochastic Oscillator
- NOM 37.93
- INTS 23.29
Stock Price Comparison Chart: NOM vs INTS
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.